Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

Nature·Sep 24

This story is reported by Nature. Read what other outlets are saying below, then open the original report for full details.